miércoles, 26 de agosto de 2020

Cystic Fibrosis News Today Daily Digest

 

Cystic Fibrosis Weekly Update


Contents:

Vertex Triple Combo, Kaftrio, Approved for CF Patients in EU With F508del Mutation

Aug 24, 2020 07:00 am | Marisa Wexler MS



Kaftrio approved in EUThe European Commission (EC) approved Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in people 12 and older who have either two F508del mutations or one F508del mutation and one minimal function mutation in the CFTR gene. The decision follows a positive opinion, supporting approval, by the Committee for Medicinal Products for Human Use, a branch […]
The post Vertex Triple Combo, Kaftrio, Approved for CF Patients in EU With F508del Mutation appeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike Vertex Triple Combo, Kaftrio, Approved for CF Patients in EU With F508del Mutation on Facebook

Recent News

NuvoAir Home Platform Classified as Class Im Medical Device
EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US
FDA Grants Orphan Drug Designation to KB407, Potential Gene Therapy for CF
Dosing Begins in Phase 1 Trial of ETD002, Potential CF Inhalation Therapy
The Painful Truth About Being a Sick Parent

No hay comentarios:

Publicar un comentario